中文摘要：

可以稳定表达治疗基因而无明显不良反应的重组腺相关病毒（rAAV）载体被认为是最有发展前景的基因治疗载体。但如何建立可以有效去除rAAV载体内具有潜在致病危害的杂质、产品质量符合临床使用要求的纯化工艺是研究人员面临的巨大挑战。其中针对载体相关性杂质的纯化工艺尤为关键,因为该类杂质的性质与真正的rAAV载体极其相似,一旦存在便难以去除,且会引起严重不良反应。以下总结了该类杂质形成的过程及有别于rAAV载体的特点,并对可以防止其生成或将其与rAAV载体有效分离的技术手段进行了评价。

英文摘要：

Recombinant adeno-associated virus（rAAV）-based vectors that can stably express therapeutic genes in vivo without detectable side-effect have shown great promise for human gene therapy.A major challenge for translation of promising research to clinical development is how to establish clinically compatible purification methods in separating rAAV from potentially pathogenic impurities,especially rAAV vector-related impurities,a class of impurities corresponding to AAV particles that closely resemble bona fide vectors and are difficult to remove.In this review we summarize the assembly process of rAAV vector-related impurities and their characteristics differed with rAAV vectors,and evaluate several current technologies to prevent their formation or separate them from rAAV stocks.